[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
The application of angiogenesis inhibitors in neurooncology is increasing. Initially, these drugs seemed to be very promising because of the surprisingly high neuroradiological response rates that were observed in first clinical trials. Meanwhile, this enthusiasm is waning, as the high response rates did not translate into substantial improvements in progression-free and overall survival. Tumor progression during or after antiangiogenic therapy is often associated with rapid clinical neurological deterioration and sometimes even with diffuse infiltrative gliomatosis-like neuroradiological phenotypes. Thus, the characterization and understanding of escape mechanisms are needed. The identification of criteria for defining the personalized use of angiogenesis inhibitors remains a challenge.
Tabatabai
G
G
Neurologische Klinik, UniversitätsSpital Zürich, Frauenklinikstrasse 26, 8091, Zürich, Schweiz. ghazaleh.tabatabai@usz.ch
Stupp
R
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005910:Glioma / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000098:blood supply / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012910:Snake Venoms / Q000009:adverse effects / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D007211:Indoles
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D011799:Quinazolines; D012910:Snake Venoms; D042461:Vascular Endothelial Growth Factor A; C422910:Cilengitide; C500926:cediranib; D007211:Indoles